Biocryst Pharmaceuticals‘ once-daily oral therapy Orladeyo (berotralstat) is now approved in Japan to prevent swelling attacks in children with hereditary angioedema (HAE) as young as 2 years old. Japan’s Ministry of Health, Labor and Welfare (MHLW) first approved Orladeyo in 2021 as a treatment for HAE…
News
Onvuzosiran, an experimental treatment for hereditary angioedema (HAE) now in Phase 3 testing, has been granted fast track designation from the U.S. Food and Drug Administration (FDA). The FDA grants this status to expedite the development and review of experimental medicines that show potential to address unmet medical needs…
Long-term preventive treatment with Takhzyro (lanadelumab-flyo) — approved in the U.S. and the European Union for nearly a decade — substantially reduces the rate of swelling attacks in people with hereditary angioedema (HAE) treated in routine clinical practice. That’s according to the final results of a Phase 4 study…
An infant with recurrent episodes of swelling in her limbs and around her eyes was ultimately diagnosed with idiopathic angioedema after tests ruled out lymphedema and other potential causes, according to a case report. The 4-month-old girl was initially referred for evaluation for possible lymphedema, a condition in which…
A woman with hereditary angioedema (HAE) gave birth to a healthy baby after being briefly exposed to Orladeyo  (berotralstat) early in her pregnancy, according to a case report from Italy. The woman became pregnant about three months after starting Orladeyo, and the fetus was exposed to the treatment…
A 7-year-old girl in Iran with repeated episodes of unexplained swelling was ultimately diagnosed with hereditary angioedema (HAE) after bruise-like discoloration appeared around one eye and then developed into swelling on one side of her face, according to a case report. Laboratory testing confirmed that the girl had type…
People with hereditary angioedema (HAE) often have misgivings about the long-term safety and feasibility of preventive treatments, so it’s crucial that their doctors stay up to date on research and guidelines to provide accurate information and facilitate collaborative treatment decisions, a study found. “This research highlights the need to…
Different types of COVID-19 vaccines may produce distinct long-term immune responses in people with hereditary angioedema (HAE), according to a small study of four patients. Researchers found that all participants developed antibodies against SARS-CoV-2 — the virus that causes COVID-19 — after vaccination, regardless of the vaccine they received.
A 19-year-old adolescent with hereditary angioedema (HAE) successfully received a kidney transplant from his mother, who also had HAE, without experiencing a swelling attack either during or immediately after surgery, according to a case report in Argentina. Both received preventive treatment before and after the procedure and fresh frozen…
People with drug-induced nonallergic angioedema caused by aspirin who have had a heart attack may still be able to receive aspirin after undergoing desensitization soon after emergency treatment, a case report from France showed. Aspirin desensitization involves giving gradually increasing aspirin doses under close medical supervision until the patient…
Recent Posts
- Despite preventive treatment, on-demand meds still needed in HAE
- I have mixed feelings about a potential gene-editing therapy for HAE
- Experimental treatment eases chronic itching, hives in clinical trials
- HAE treatment for preventing swelling attacks wins approval in Canada
- Recurring, severe abdominal pain may be sign of angioedema in children